S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NASDAQ:DCPH

Deciphera Pharmaceuticals - DCPH Stock Forecast, Price & News

$16.58
-0.13 (-0.78%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$16.15
$17.16
50-Day Range
$14.85
$22.10
52-Week Range
$6.51
$22.76
Volume
704,075 shs
Average Volume
1.06 million shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Deciphera Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
34.0% Upside
$22.22 Price Target
Short Interest
Healthy
9.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.55
Upright™ Environmental Score
News Sentiment
0.67mentions of Deciphera Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($2.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

30th out of 1,029 stocks

Pharmaceutical Preparations Industry

12th out of 504 stocks

DCPH stock logo

About Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Stock News Headlines

The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Deciphera Pharma Prices Public Offering Of 6.94 Mln Shares At $18/shr
Why Deciphera Pharmaceuticals Stock Is Nosediving
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Where Deciphera Pharmaceuticals Stands With Analysts
DCPH Deciphera Pharmaceuticals, Inc.
4 Analysts Have This to Say About Deciphera Pharmaceuticals
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Company Calendar

Last Earnings
11/02/2021
Today
2/07/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.22
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+32.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-299,960,000.00
Net Margins
-177.53%
Pretax Margin
-181.63%

Debt

Sales & Book Value

Annual Sales
$96.15 million
Book Value
$5.21 per share

Miscellaneous

Free Float
64,729,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
0.70

Key Executives

  • Steven L. Hoerter
    President & Chief Executive Officer
  • Tucker Kelly
    Chief Financial Officer, Treasurer & Executive VP
  • Daniel L. FlynnDaniel L. Flynn
    Chief Scientific Officer & Executive VP
  • Rodrigo Ruiz Soto
    Senior Vice President-Clinical Development
  • Stephen B. Ruddy
    Chief Technical Officer & SVP













DCPH Stock - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCPH shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price forecast for 2023?

9 Wall Street analysts have issued 12 month target prices for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they expect the company's share price to reach $22.22 in the next year. This suggests a possible upside of 34.0% from the stock's current price.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2023?

Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of the year. Since then, DCPH stock has increased by 1.2% and is now trading at $16.58.
View the best growth stocks for 2023 here
.

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our DCPH earnings forecast
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.29) by $0.08. The company earned $23.22 million during the quarter, compared to analysts' expectations of $23.73 million. Deciphera Pharmaceuticals had a negative net margin of 177.53% and a negative trailing twelve-month return on equity of 63.88%. During the same period in the prior year, the firm posted ($1.13) earnings per share.

What guidance has Deciphera Pharmaceuticals issued on next quarter's earnings?

Deciphera Pharmaceuticals updated its fourth quarter 2022 earnings guidance on Tuesday, January, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36.00 million-$36.00 million, compared to the consensus revenue estimate of $34.83 million.

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.50%), Allspring Global Investments Holdings LLC (0.14%), Hennion & Walsh Asset Management Inc. (0.10%), TD Asset Management Inc (0.06%), Inspire Investing LLC (0.02%) and ProShare Advisors LLC (0.02%). Insiders that own company stock include Brightstar Associates Llc, Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $16.58.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.12 billion and generates $96.15 million in revenue each year. The company earns $-299,960,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

The company employs 280 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.

This page (NASDAQ:DCPH) was last updated on 2/8/2023 by MarketBeat.com Staff